Published in Transl Cancer Res on August 01, 2016
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One (2008) 8.97
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Dissecting the metastatic cascade. Nat Rev Cancer (2004) 6.32
Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell (2012) 5.53
Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78
Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77
Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell (2012) 4.51
Evolution of the cancer stem cell model. Cell Stem Cell (2014) 4.38
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature (2015) 4.18
Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia (2010) 3.93
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature (2015) 3.77
Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev (2004) 3.65
Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest (2012) 3.45
Origins of metastatic traits. Cancer Cell (2013) 2.49
Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res (2009) 2.28
Regulation of actin-based cell migration by cAMP/PKA. Biochim Biophys Acta (2004) 2.15
The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia (2010) 2.12
Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer (2014) 2.09
EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget (2015) 1.92
Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets (2010) 1.91
Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol (2009) 1.90
Pharmacological PKA inhibition: all may not be what it seems. Sci Signal (2008) 1.89
Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene (2004) 1.72
The cyclic AMP-mediated stimulation of cell proliferation. Trends Biochem Sci (1989) 1.64
Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature (2015) 1.53
Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression. Cell Tissue Res (2011) 1.53
Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol (Oxf) (2011) 1.43
Framework models of tumor dormancy from patient-derived observations. Curr Opin Genet Dev (2010) 1.41
Cell biology of the movement of breast cancer cells: intracellular signalling and the actin cytoskeleton. Cancer Lett (2009) 1.40
Metastatic colonization by circulating tumour cells. Nature (2016) 1.31
Tumorigenesis: it takes a village. Nat Rev Cancer (2015) 1.27
Protein kinase A as target for novel integrated strategies of cancer therapy. Ann N Y Acad Sci (2002) 1.21
A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res (2015) 1.11
Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts. Cell Biochem Biophys (1998) 1.10
Regulatory subunits of PKA and breast cancer. Ann N Y Acad Sci (2002) 1.09
Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2008) 1.07
cAMP-dependent protein kinase is essential for hypoxia-mediated epithelial-mesenchymal transition, migration, and invasion in lung cancer cells. Cell Signal (2012) 1.06
cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse. Mol Cell Endocrinol (2013) 0.97
Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects. Clin Cancer Res (1999) 0.97
Tumor reversion: protein kinase A isozyme switching. Ann N Y Acad Sci (2005) 0.95
Targeted deletion of Prkar1a reveals a role for protein kinase A in mesenchymal-to-epithelial transition. Cancer Res (2008) 0.95
Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proc Natl Acad Sci U S A (2013) 0.95
3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res (1993) 0.95
The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells. Cells Tissues Organs (2010) 0.94
Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. Science (2016) 0.92
Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility. Clin Exp Metastasis (2000) 0.90
PKA phosphorylation redirects ERα to promoters of a unique gene set to induce tamoxifen resistance. Oncogene (2012) 0.89
Protein kinase A alterations in endocrine tumors. Horm Metab Res (2012) 0.80
Different effects of adenylyl cyclase activators and phosphodiesterases inhibitors on cervical cancer (HeLa) and breast cancer (MCF-7) cells proliferation. Toxicol Mech Methods (2014) 0.78
Design of Next-Generation G Protein-Coupled Receptor Drugs: Linking Novel Pharmacology and In Vivo Animal Models. Annu Rev Pharmacol Toxicol (2016) 0.76
Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer. Cancer Res (2015) 0.98
TGF-β Stimulation of EMT Programs Elicits Non-genomic ER-α Activity and Anti-estrogen Resistance in Breast Cancer Cells. J Cancer Metastasis Treat (2017) 0.75